Positive FDA findings confirm integrity of Ecuadorian shrimp exports. The U.S. Food and Drug Administration (FDA) has released results from its 2022–2024 sampling and analysis programme focused on economically motivated adulteration, specifically short-weighting, in imported frozen seafood. The FDA tested a total of 28 retail-packaged frozen seafood samples (25 shrimp, 2 squid, and 1 tilapia), each consisting of 48 units from the same production lot, using the AOAC Method 963.18 to assess compliance with net weight declarations.
Of the sampled shrimp products, none from Ecuador exhibited short‑weighting violations, meaning the actual net weight matched the declared net weight on the label. This is a notable outcome, especially in the context of the program overall, where 36 % of total samples (10 out of 28) were found to be violative, with deviations ranging from 2.3 % to 9.9 %.
This finding affirms the rigorous standards upheld in Ecuadorian shrimp exports and underscores the vital role of compliance with international requirements. Accurate net weight labelling protects transparency in trade, reinforces consumer confidence, and helps prevent fraudulent practices such as economically motivated adulteration, where products are deliberately made to appear heavier or more substantial than they truly are.
Source